Cytokinetics to report Q1 2026 results on May 5 with a follow-up earnings call.

Cytokinetics, a cardiovascular biopharmaceutical company, announced it will release its first quarter 2026 financial results on May 5, 2026, at 4:00 PM Eastern Time. Following the announcement, senior management will hold a conference call to discuss the results and provide business updates. The company is known for its cardiac muscle disease treatments, including the approved drug MYQORZO® (aficamten) and investigational therapies like omecamtiv mecarbil and ulacamten. Investors can access the webcast via Cytokinetics' website, with a replay available for six months.